Rituximab
Top View
- Epidermal Growth Factor Receptor Mutation Mediates Cross- Resistance to Panitumumab and Cetuximab in Gastrointestinal Cancer
- PATIENT FACT SHEET (Rituxan and Mabthera)
- Brentuximab Vedotin in Combination with Rituximab, Cyclophosphamide
- Abstract #630 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: the Orcharrd Study (OMB110928)
- Randomised Controlled Trial Comparing Ofatumumab to Rituximab
- Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
- A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab As Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression
- Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma Matthew J
- Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, Or Pancreatic Cancer: an Open-Label, Multicenter, Phase I/II Trial
- Zevalin, INN-Ibritumomab Tiuxetan
- Impact of the Subcutaneous Formulations of Trastuzumab And
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab) Label
- Ibritumomab Tiuxetan (Interim Monograph)
- Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma J
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/ Cmet Bispecific
- 761150Orig1s000
- And Trastuzumab (Herceptin) Using Hyaluronidase